-
公开(公告)号：EP3237401B1
公开(公告)日：2019-03-06
申请号：EP15821169.8
申请日：2015-12-11
申请人： Pfizer Inc.
发明人： BAHNCK, Kevin , CANTERBURY, Daniel , EDMONDS, David James , FUTATSUGI, Kentaro , LEE, Esther Cheng Yin , MENHAJI-KLOTZ, Elnaz , POLIVKOVA, Jana , STANTON, Robert Vernon
IPC分类号： C07D401/14 , A61K31/4709 , A61P3/10 , A61P9/00 , A61P9/12 , A61P29/00
-
公开(公告)号：EP3500564B1
公开(公告)日：2020-10-07
申请号：EP17761332.0
申请日：2017-08-09
申请人： Pfizer Inc.
发明人： BOEHM, Markus , CABRAL, Shawn , DOWLING, Matthew S. , FUTATSUGI, Kentaro , HUARD, Kim , LEE, Esther Cheng Yin , LI, Qifang , LONDREGAN, Allyn T. , POLIVKOVA, Jana , PRICE, David A.
IPC分类号： C07D401/14 , A61K31/506 , A61P3/00
-
公开(公告)号：EP3500564A1
公开(公告)日：2019-06-26
申请号：EP17761332.0
申请日：2017-08-09
申请人： Pfizer Inc.
发明人： BOEHM, Markus , CABRAL, Shawn , DOWLING, Matthew S. , FUTATSUGI, Kentaro , HUARD, Kim , LEE, Esther Cheng Yin , LI, Qifang , LONDREGAN, Allyn T. , POLIVKOVA, Jana , PRICE, David A.
IPC分类号： C07D401/14 , A61K31/506 , A61P3/00
摘要： Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
-
公开(公告)号：EP3055300B1
公开(公告)日：2018-03-07
申请号：EP14799209.3
申请日：2014-09-25
申请人： Pfizer Inc.
发明人： BAHNCK, Kevin Barry , LEE, Esther Cheng Yin , FUTATSUGI, Kentaro , MATHIOWETZ, Alan Martin , EDMONDS, David James , MENHAJI-KLOTZ, Elnaz , STANTON, Robert Vernon
IPC分类号： C07D401/14 , A61K31/4545 , A61P3/10 , A61P9/00 , A61P25/00 , A61P29/00
CPC分类号： C07D401/14
摘要： Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
-
公开(公告)号：EP3237401A1
公开(公告)日：2017-11-01
申请号：EP15821169.8
申请日：2015-12-11
申请人： Pfizer Inc.
发明人： BAHNCK, Kevin , CANTERBURY, Daniel , EDMONDS, David James , FUTATSUGI, Kentaro , LEE, Esther Cheng Yin , MENHAJI-KLOTZ, Elnaz , POLIVKOVA, Jana , STANTON, Robert Vernon
IPC分类号： C07D401/14 , A61K31/4709 , A61P3/10 , A61P9/00 , A61P9/12 , A61P29/00
CPC分类号： C07D401/14
摘要： Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
摘要翻译： 本文提供了前列腺素EP3受体的拮抗剂1a或1b，制备所述拮抗剂的方法，以及包括将所述拮抗剂施用于有此需要的哺乳动物的方法。 （式I）
-
公开(公告)号：EP2836490B1
公开(公告)日：2017-06-14
申请号：EP13720084.6
申请日：2013-04-01
申请人： Pfizer Inc.
发明人： BHATTACHARYA, Samit Kumar , CAMERON, Kimberly O'Keefe , DOWLING, Matthew Scott , EBNER, David Christopher , FERNANDO, Dilinie Prasadhini , FILIPSKI, Kevin James , KUNG, Daniel Wei-Shung , LEE, Esther Cheng Yin , SMITH, Aaron Christopher , TU, Meihua Mike
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/404 , A61K31/416 , C07D231/56 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , C07D209/42 , A61P3/04 , A61P35/00 , A61P3/10
CPC分类号： C07D413/12 , A61K31/404 , A61K31/416 , C07D209/42 , C07D231/56 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/14
-
公开(公告)号：EP3055300A1
公开(公告)日：2016-08-17
申请号：EP14799209.3
申请日：2014-09-25
申请人： Pfizer Inc.
发明人： BAHNCK, Kevin Barry , LEE, Esther Cheng Yin , FUTATSUGI, Kentaro , MATHIOWETZ, Alan Martin , EDMONDS, David James , MENHAJI-KLOTZ, Elnaz , STANTON, Robert Vernon
IPC分类号： C07D401/14 , A61K31/4545 , A61P3/10 , A61P9/00 , A61P25/00 , A61P29/00
CPC分类号： C07D401/14
摘要： Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
摘要翻译： 本文提供前列腺素EP3受体的拮抗剂，制备所述拮抗剂的方法，以及包括向有需要的哺乳动物施用所述拮抗剂的方法。
-
公开(公告)号：EP2673260B1
公开(公告)日：2016-08-17
申请号：EP12704132.5
申请日：2012-01-25
申请人： Pfizer Inc.
发明人： ASPNES, Gary Erik , DIDIUK, Mary Theresa , FILIPSKI, Kevin James , GUZMAN-PEREZ, Angel , LEE, Esther Cheng Yin , PFEFFERKORN, Jeffrey Allen , STEVENS, Benjamin Dawson , TU, Meihua Mike
IPC分类号： C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D249/06 , C07D249/08 , C07D261/08
CPC分类号： C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
-
公开(公告)号：EP2836490A2
公开(公告)日：2015-02-18
申请号：EP13720084.6
申请日：2013-04-01
申请人： Pfizer Inc.
发明人： BHATTACHARYA, Samit Kumar , CAMERON, Kimberly O'Keefe , DOWLING, Matthew Scott , EBNER, David Christopher , FERNANDO, Dilinie Prasadhini , FILIPSKI, Kevin James , KUNG, Daniel Wei-Shung , LEE, Esther Cheng Yin , SMITH, Aaron Christopher , TU, Meihua Mike
IPC分类号： C07D403/12 , C07D401/14 , C07D405/14 , C07D413/14 , A61K31/404 , A61K31/416 , C07D231/56 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , C07D209/42 , A61P3/04 , A61P35/00 , A61P3/10
CPC分类号： C07D413/12 , A61K31/404 , A61K31/416 , C07D209/42 , C07D231/56 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D405/12 , C07D405/14 , C07D413/14
摘要： The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
-
公开(公告)号：EP2673260A1
公开(公告)日：2013-12-18
申请号：EP12704132.5
申请日：2012-01-25
申请人： Pfizer Inc.
发明人： ASPNES, Gary Erik , DIDIUK, Mary Theresa , FILIPSKI, Kevin James , GUZMAN-PEREZ, Angel , LEE, Esther Cheng Yin , PFEFFERKORN, Jeffrey Allen , STEVENS, Benjamin Dawson , TU, Meihua Mike
IPC分类号： C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D249/06 , C07D249/08 , C07D261/08
CPC分类号： C07D401/04 , A61K31/506 , C07D207/34 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/18 , C07D231/54 , C07D231/56 , C07D233/61 , C07D233/64 , C07D233/68 , C07D233/70 , C07D233/84 , C07D239/28 , C07D249/06 , C07D249/08 , C07D261/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/14 , C07D487/04
摘要： The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3，A 1，A 2，A 3，A 4，L，B 1，B 2，B 3和B 4如本文所定义。 已发现式I化合物可用作胰高血糖素拮抗剂或反向激动剂。 因此，式I化合物及其药物组合物可用于治疗由胰高血糖素介导的疾病，病症或病症。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.055 秒)
